Drug or intervention
Dupilumab Clinical Trials
Studies that test Dupilumab, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 78Major Depressive Disorder
Dupilumab in Major Depressive Disorder
This study aims primarily to test target engagement of dupilumab by assessing changes in peripheral immune markers following interleukin-4 receptor alpha (IL-4Rα) blockade in adults with major depressive disorder (MDD).
- Trial name
- NCT07908563
- Testing
- Dupilumab Injection
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Atopic Dermatitis
A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis
This study will describe safety of dupilumab in adult participants with atopic dermatitis. It will also look at the improvement of atopic dermatitis signs and symptoms in these participants.
- Trial name
- NCT07905547
- Testing
- Dupilumab
- Volunteers
- 56 people
- Sponsor
- Sanofi
Atopic Dermatitis
ADBest TREAT Registry
Atopic dermatitis is a chronic inflammatory skin disease associated with intense pruritus, recurrent eczematous lesions, sleep disturbance, and reduced quality of life.
- Trial name
- ADBest-TREAT (NCT07904546)
- Testing
- Abrocitinib, Baricitinib, Upadacitinib
- Where
- Germany
- Volunteers
- 5,000 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Pruritis
Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
The goal of this study is to test the efficacy of Dupixent in improving post-burn itching symptoms versus the current standard of care.
- Trial name
- NCT06226610
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Akron Children's Hospital
Atopic Dermatitis
Microbiome in Atopic Dermatitis Under Systemic Therapy
The skin microbiome plays a role in the pathogenesis of atopic dermatitis. However, it is unclear whether the range of microbiota on the skin is the cause or consequence of atopic skin inflammation.
- Trial name
- BIO-AD (NCT05099315)
- Testing
- not applicable, observational study
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- Charite University, Berlin, Germany
Atopic Dermatitis
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema).
- Trial name
- Tilrek (NCT07783425)
- Testing
- Tilrekimig, Dupilumab
- Where
- 32 sites in United States, Japan
- Volunteers
- 1,375 people
- Sponsor
- Pfizer
Dermatitis, Atopic
A Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other Therapies
The purpose of this observational study is to learn about the effects of the study medicine (called abrocitinib) for the treatment of severe atopic dermatitis in people that were moved from previous novel therapies, known as…
- Trial name
- NCT07887867
- Testing
- abrocitinib
- Volunteers
- 120 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
LPS18583 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 4 study with 2 treatment groups.
- Trial name
- AEOLUS (NCT07053423)
- Testing
- Dupilumab
- Where
- 85 sites in United States, Argentina and 20 more
- Volunteers
- 218 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease (COPD)
This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
This study is researching a drug called dupilumab, referred to as "study drug". The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce…
- Trial name
- MISSION (NCT07587658)
- Testing
- dupilumab
- Where
- United States
- Volunteers
- 754 people
- Sponsor
- Regeneron Pharmaceuticals
COPD (Chronic Obstructive Pulmonary Disease)
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD.
- Trial name
- STRIDE (NCT07612878)
- Testing
- Cohort 1: Dupilumab, Cohort 2: usual care only
- Where
- 7 sites in United States
- Volunteers
- 350 people
- Sponsor
- Sanofi
Completed, with results posted
All 79Keloid
Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids
The study investigates the efficacy and safety of dupilumab in the treatment of keloids
- Trial name
- NCT05128383
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Beth Israel Deaconess Medical Center
Allergic Fungal Rhinosinusitis
Dupilumab in Allergic Fungal Rhinosinusitis (AFRS)
Primary Objective: To evaluate the efficacy of treatment with dupilumab to reduce sinus opacification in a population with allergic fungal rhinosinusitis (AFRS) Secondary Objectives: To evaluate the efficacy of treatment with…
- Trial name
- AIMS (NCT04684524)
- Testing
- Dupilumab SAR231893
- Where
- 47 sites in United States, Argentina and 7 more
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Sanofi
Chronic Rhinosinusitis With Nasal Polyps
Mechanisms of Smell Improvement With Dupilumab.
This study seeks to explore the mechanism through which dupilumab improves olfactory cleft inflammation in patients with chronic sinusitis with nasal polyps (CRSwNP).
- Trial name
- NCT05964465
- Testing
- Dupilumab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Medical University of South Carolina
Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis
Dupilumab in CRSsNP
Primary Objective: To evaluate the efficacy of dupilumab as assessed by the reduction at Week 24 in sinus opacification on computerized tomography (CT) scan in the dupilumab group only Secondary Objectives: To evaluate the…
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis, Sinus Disorder
- Trial name
- Liberty CRSsNP (NCT04678856)
- Testing
- Dupilumab SAR231893
- Where
- 58 sites in United States, Argentina and 11 more
- Volunteers
- 71 people
- Sponsor
- Sanofi
Bullous Pemphigoid
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
The main purpose of this study is to investigate whether dupilumab is effective and safe for the treatment of bullous pemphigoid. Dupilumab is a type of drug called a "monoclonal antibody".
- Trial name
- LIBERTY-BP (NCT04206553)
- Testing
- dupilumab, Oral corticosteroids (OCS)
- Where
- 53 sites in United States, Australia and 7 more
- Volunteers
- 106 people
- Sponsor
- Regeneron Pharmaceuticals